We are a small group of highly committed and seasoned scientists who have taken the size and severity of this global challenge personally and pledged to commit ourselves to address this before it becomes a bigger global health nightmare.
We are proud of our ongoing commitment to the research and development of new antibacterial agents and anti-cancer treatments, and we are working hard to ensure that both individual patients and society will continue to benefit from our Go-to-Globe Strategy.
The AMR problem and the unmet need
The last novel class of antibacterial agents to be licensed was discovered in 1987. Antimicrobial Resistance (AMR) is one of the major challenges of our time, with devastating and long-lasting consequences. Without effective antimicrobials, common infections can become life-threatening, and even routine treatments such as surgical procedures and chemotherapy would not be possible, making any medical intervention almost impossible.
Stepping up Cancer therapeutics to the next level
Our research programs focus on discovering affordable, differentiated, small molecule therapeutics for highly hypoxic tumors where adenosine plays a pivotal role in creating an immunosuppressive and tumor-promoting environment.
We believe our deep understanding of medicinal chemistry and the tumor microenvironment has the potential to render the current standard of care therapies more effective with sustained anti-tumor responses. Our research programs focus on discovering differentiated and affordable small molecule therapeutics for treating recalcitrant tumors
News & Announcements
Dr. Anand Anandkumar, co-founder and CEO, participated in a panel discussion on the theme “Investing in the present and securing our future together: accelerating multisectoral global, regional and national actions to address antimicrobial resistance” at the United Nations Headquarters in New York.
September 25, 2024 Published in Devex
Bugworks Research Inc. featured in The Better India for our ongoing efforts against antibiotic resistance
September 18, 2024 Published in The Better India
Bala Subramanian, co-founder and COO, presents Bugworks Research Inc.’s innovative antibiotic BWC0977 at the prestigious World AMR Congress
September 6, 2024 Published in Contagionlive
Dr. Anand Anandkumar, the co-founder and CEO of Bugworks Research Inc., was invited as a guest on an episode of the One World, One Health podcast.
August 2, 2024 Published In One Health Trust Channel
Our Team
